Clinical trials: Squamous Cell Cancer
Squamous Cell Carcinoma of Head and Neck
A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)
The primary objective of this study is to compare the change in tumour size per Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1) in recurrent or metastatic SCCHN patients treated with setanaxib and…
- Trial name
- NCT05323656
- Testing
- Setanaxib, Pembrolizumab
- Where
- 24 sites in United States, France and 5 more
- Volunteers
- 55 people
- Sponsor
- Calliditas Therapeutics Suisse SA
Head and Neck Cancer
Gemcitabine and Docetaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00248560
- Testing
- docetaxel, Gemcitabine
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Solid Tumors
A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)
The purpose of this study is to determine the safety, tolerability, and efficacy of epacadostat when given in combination with nivolumab and ipilimumab, and in combination with nivolumab and lirilumab, in participant with…
- Trial name
- NCT03347123
- Testing
- Epacadostat, Nivolumab, Ipilimumab
- Where
- 5 sites in United States
- Volunteers
- 11 people
- Sponsor
- Incyte Corporation
Lung Cancer, Non-Small Cell Lung Cancer
LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Background: Over 230,000 new lung cancer cases are diagnosed every year in the United States (U.S.) About 80% of lung cancers are non- small cell lung cancer (NSCLC).
- Conditions
- Lung Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma of Lung
- Trial name
- NCT04027946
- Testing
- LMB-100, pembrolizumab, Mesothelin Expression
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Squamous Cell Carcinoma
Radiotherapy With Pembrolizumab in Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Randomized phase II study of immune stimulation with Pembrolizumab and radiotherapy in second line therapy of metastatic head and neck squamous cell carcinoma.
- Trial name
- NCT03386357
- Testing
- A (pembrolizumab+RT), B (pembrolizumab)
- Where
- 7 sites in Germany
- Volunteers
- 115 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Cancer, Head and Neck Cancer
Radiotherapy Plus Panitumumab Compared to Chemoradiotherapy With Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck
The purpose of this study is to estimate, with pre-specified precision, the difference in local-regional control (LRC) rate at 2 years in subjects receiving chemoradiotherapy (CRT) or panitumumab plus radiotherapy (PRT) as first…
- Conditions
- Cancer, Head and Neck Cancer, Oncology, Squamous Cell Carcinoma
- Trial name
- NCT00547157
- Testing
- Panitumumab, Cisplatin
- Volunteers
- 152 people
- Sponsor
- Amgen
Squamous Cell Carcinoma of the Head and Neck
Margin-Based Vs. Robust Photon Radiotherapy Planning in IMRT of HN-SQCC
This is a research study to evaluate the quality of life and amount of dry mouth experienced as a result of radiotherapy in subjects who have squamous cell carcinoma of the head and neck (HN-SQCC).
- Trial name
- NCT03552965
- Testing
- Robust Radiotherapy planning, Margin-Based Radiotherapy planning
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Arkansas
Oral Squamous Cell Carcinoma, Neoadjuvant Chemotherapy
Melatonin Effect in Combination With Neoadjuvant Chemotherapy to Clinical Response in Locally Advanced Oral Squamous Cell Carcinoma
Backgrounds Squamous cell carcinoma of the oral cancer (OSCC) is the sixth most common malignancy. Surgery is the mainstay of treatment for oral cancers.
- Trial name
- NCT04137627
- Testing
- Melatonin 20 MG Oral Capsule
- Where
- Indonesia
- Volunteers
- 50 people
- Sponsor
- Universitas Indonesia
Distal Urethral Cancer, Proximal Urethral Cancer
Gemcitabine Hydrochloride and Cisplatin Before Surgery in Treating Patients With Muscle Invasive Bladder Cancer
The purpose of this research study is to find out what effects, good and/or bad, dose-dense (every 14 days) chemotherapy with gemcitabine (gemcitabine hydrochloride) and cisplatin given before surgery have on patients and their…
- Conditions
- Distal Urethral Cancer, Proximal Urethral Cancer, Squamous Cell Carcinoma of the Bladder, Stage II Bladder Cancer
- Trial name
- NCT01611662
- Testing
- gemcitabine hydrochloride, cisplatin, therapeutic conventional surgery
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Fox Chase Cancer Center
Radiation Dermatitis
Low Level Laser Therapy for Radiation Induced Dermatitis in H & N Squamous Cell Carcinoma
This study will assess the efficacy of LLLT to mitigate and ameliorate the acneiform-rash, radiation dermatitis, and pain, while assessing its impact on patient reported quality of life.
- Trial name
- NCT02384434
- Testing
- THOR Laser System for Low Level Laser Therapy (LLLT)
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Heath Skinner
NSCLC (Non-small Cell Lung Cancer)
A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients
This is a Phase III, Randomized, Open-label, Efficacy and Safety Study of Crizotinib single agent versus Chemotherapy Regimens (Pemetrexed/Cisplatin or Pemetrexed/Carboplatin) in First-Line ALK (Anaplastic Lymphoma Kinase)…
- Trial name
- NCT01639001
- Testing
- Crizotinib, Pemetrexed/Cisplatin, Pemetrexed/Carboplatin
- Where
- 47 sites in China, Hong Kong and 3 more
- Volunteers
- 207 people
- Sponsor
- Pfizer
Advanced Cutaneous Squamous Cell Carcinoma
Study of Ruxolitinib in Solid Organ Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma
In this open-label, multicenter, Phase II study, the investigators propose to evaluate the efficacy of ruxolitinib, an orally administered inhibitor of JAK1/2, in solid organ transplant recipients with advanced cSCC.
- Trial name
- NCT04807777
- Testing
- Ruxolitinib
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Columbia University
Lung Cancer
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from…
- Trial name
- NCT00729612
- Testing
- carboplatin, paclitaxel albumin-stabilized nanoparticle formulation, protein expression analysis
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Greg Otterson
Anal Cancer, Rectal Cancer
A Phase 2 Study of Axalimogene Filolisbac (ADXS11-001) in Participants With Carcinoma of the Anorectal Canal
This is a single arm Phase 2 study. Stage 1 and 2 of the study are monotherapy evaluations of ADXS11-001 in 31 and 24 participants, respectively with persistent/recurrent, loco-regional or metastatic squamous cell carcinoma…
- Trial name
- NCT02399813
- Testing
- Axalimogene filolisbac
- Where
- 10 sites in United States
- Volunteers
- 36 people
- Sponsor
- Advaxis, Inc.
Non-Small-Cell Lung Carcinoma
Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study
This is a Japan Extension Study of Global Study MK-3475-189 (NCT02578680). This is an efficacy and safety study of pembrolizumab (MK-3475) combined with pemetrexed/platinum chemotherapy versus pemetrexed/platinum chemotherapy…
- Trial name
- NCT03950674
- Testing
- Pembrolizumab 200 mg, Cisplatin, Carboplatin
- Where
- 10 sites in Japan
- Volunteers
- 40 people
- Sponsor
- Merck Sharp & Dohme LLC